Cancer Nanomedicine: Dr Edward Chow and team highlight the clinical translation of novel drug delivery and imaging agents

Cancer is projected to account for over 13 million deaths worldwide by 2030, and is the second leading cause of death in the United States. For years, researchers have been developing promising new approaches to improve the safety and efficacy of both cancer therapy and imaging. These include the use of nanotechnology, which has enabled

CSI staff bring Christmas joy to occupants at Ren Ci Hospital

In keeping with the Christmas season of giving, a group of CSI researchers and staff organised a fund-raising project for residents at the Nursing and Long Term Care Units of Ren Ci Hospital. The residents were presented with gift packs on 20th December 2013 and enjoyed Christmas carols by the volunteers. At Ren Ci’s Nursing

Massachusetts Governor, delegates visit NUS

NUS hosted Mr Deval Patrick, Governor of the Commonwealth of Massachusetts and delegates from the US on 16 December 2013. The visitors included Mr Gregory Bialecki, Secretary of Housing and Economic Development, Commonwealth of Massachusetts and Co-Chair, Board of Directors, Massachusetts Life Sciences Center; Dr Susan Windham-Bannister, President and CEO, Massachusetts Life Sciences Center; and

Secreted Frizzled Related Proteins: Implications in Cancers (BBA – Reviews on Cancer, Dec 2013)

The Wnt (wingless-type) signalling pathway plays an important role in embryonic development, tissue homeostasis, and tumour progression because of its effect on cell proliferation, migration, and differentiation. Secreted frizzled-related proteins (SFRPs) are extracellular inhibitors of Wnt signalling that act by binding directly to Wnt ligands or to Frizzled receptors. In recent years, aberrant expression of

New biomarker discovery to improve diagnosis, prognosis and treatment of Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. A new biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), has been found to have potential in improving the diagnosis, prognosis and treatment of this disease. Led by Dr Polly Chen, Special Fellow at from

Research findings pave way for acute myeloid leukemia treatment

Acute myeloid leukemia (AML), a cancer arising from the abnormal growth in the blood-forming tissue of the bone marrow, is the most common type of acute leukemia affecting adults. It can lead to death within months, or even weeks if left untreated. The identification of a therapeutic target and anti-cancer drugs by a group of